Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (225) clinical trials

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma Acral Melanoma or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

OBJECTIVES: Primary - To estimate the objective tumor response rate in patients with KIT-positive, unresectable, locally advanced or metastatic acral or mucosal melanoma treated with dasatinib monotherapy. Secondary - To estimate the response duration in patients treated with this drug. - To estimate the progression-free survival of patients treated with ...

Phase

Safety Tolerability and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and ...

Phase

Potential Research Study Participant Registry

Methods: Subjects will self identify themselves via the UCDMC Dermatology website to complete a survey regarding their interest in learning about future dermatology clinical research projects. Subjects provide contact information and check of a list of potential topics of interest. Procedures: Potential participants will find a link on the UCDMC ...

Phase N/A

Natural Killer Cells and Bortezomib to Treat Cancer

Natural killer (NK) cells are innate immune lymphocytes that are identified by the expression of the CD56 surface antigen and the lack of CD3. Unlike antigen specific T cells, NK cells do not require the presence of a specific tumor antigen for the recognition and killing of cancer cells. Our ...

Phase

Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

OBJECTIVES: Primary - To determine the response rate in patients with relapsed or refractory melanoma that expresses wild-type p53 and S100B treated with pentamidine. Secondary - To observe the effect of this drug on the expression of S100B and p21 in tumor biopsy samples. - To observe the effect of ...

Phase

Study of Genes and Environment in Patients With Cancer in East Anglia Trent or West Midlands Regions of the United Kingdom

OBJECTIVES: - To obtain epidemiological information and biological material on a population-based series of cancer cases, including malignant melanoma, lymphoma, bladder, kidney, esophageal, and pancreatic cancer, and brain tumors. - Identify novel cancer susceptibility genes, by comparison of genotype frequencies in cases with the corresponding frequencies in large control series. ...

Phase N/A

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Melanoma is a cutaneous neoplasm known for its high aggressiveness, its early dissemination of metastases, and its poor prognosis once metastasized. Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma, with reported response rates of about 10%. This poor outcome is assumed to be due ...

Phase

Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

OBJECTIVES: Primary - To describe the safety and toxicity of the combination of dasatinib and bevacizumab in patients with advanced solid tumors that have progressed on standard therapy. - To find the maximum tolerated dose or recommended phase II dose of this combination. - To describe the biochemical changes in ...

Phase

Chemotherapy and Total-Body Irradiation Followed By Laboratory-Treated Autologous Lymphocytes Aldesleukin and Vaccine Therapy in Treating Patients With Metastatic Melanoma

OBJECTIVES: Primary - Determine if the administration of anti-gp100:154-162 and anti-MART-1:27-35 T-cell receptor (TCR) gene-engineered peripheral blood lymphocytes (PBL), high-dose aldesleukin, and gp100:154-162 or MART-1:26-35(27L) peptide vaccination following a chemoradiation lymphodepleting preparative regimen results in complete clinical tumor regression in patients with metastatic melanoma (closed as of 09/21/09). - Determine ...

Phase

Survivin Peptide Vaccination for Patients With Advanced Melanoma Pancreatic Colon and Cervical Cancer

As prognosis of advanced melanoma, pancreatic, colon and cervical cancer remains gloomy, new therapeutic modalities have to be developed to improve the patient´s clinical outcome. Immunotherapy, which targets tumor associated antigens of tumor cells or tumor stroma, is currently an intensively investigated, novel therapeutic option. As survivin is expressed both ...

Phase